Stay updated with breaking news from Highly Selective. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
17.10.2023 - Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancersSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. ...
Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated...
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy ParticipantsÂ
Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...